Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
RNA
Avidity Biosciences
$46.97
Login to see Avidity Biosciences (RNA) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Upgraded on attractively valued
Chart
$46.62 (+0.75%)
$33.57 (+39.92%)
$28.33 (+65.80%)
$50.45 (-6.90%)
RNA has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
High volatilty
RNA overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
RNA Analysts opinion is positive and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
RNA Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayRNA Earnings
The TTM reflects 12-month period, providing review of RNA financial performance.
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
What is RNA current stock price?
What are RNA stock strengths?
What risks are associated with RNA stock?
When is RNA next earnings report?
What is RNA market cap and volume?
What is RNA's current Stock IQ?
Should I buy RNA stock right now?
Is RNA a Strong Buy right now?
What does a 'Strong Buy' rating mean for RNA?
What does a 'Strong Sell' rating mean for RNA?
What factors influence RNA's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
RNA
Avidity Biosciences
Current Price
$46.97
Stock Insights
Strengths
Upgraded on attractively valued
Login to unlock Avidity Biosciences (RNA) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$46.62 (+0.75%)
$33.57 (+39.92%)
$28.33 (+65.80%)
$50.45 (-6.90%)
RNA Analysts Opinion
RNA Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
RNA Analysts opinion is positive and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
RNA Street view is extremely bullish and have positive views on the near-term outlook
RNA has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
High volatilty
Average key support and resistance price levels.
Login to displayRNA Earnings
The TTM data reflects the most recent 12-month period, providing overview of RNA financial performance.
RNA Financial Health
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
RNA Latest Analysis
Avidity Biosciences (RNA) Announces Positive One-Year Data For its Del-Zota. Avidity Biosciences Inc. (NASDAQ:RNA) is one of the Best Performing Long Term Stocks According to Analysts. On September 10 Avidity Biosciences Inc. (NASDAQ:RNA) announced positive one-year data for its del-zota in the EXPLORE44 and EXPLORE44-OLE trials for Duchenne muscular dystrophy patients amenable to exon 44 skipping. Management noted that the data show a reversal of [….]
Wed Sep 24, 2025
Roth Capital Initiates Coverage of Avidity Biosciences (RNA) with Buy Recommendation. Fintel reports that on September 17 2025 Roth Capital initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Buy recommendation.
Thu Sep 18, 2025
Avidity Biosciences CMO sells $70k in shares.
Wed Sep 17, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings